Genotype-guided antiplatelet treatment versus conventional therapy: A systematic review and meta-analysis.
Hanxu ZhangQian XiangZhiyan LiuGuangyan MuQiufen XieShuang ZhouLingyue MaZining WangKun HuZhe WangYi Min CuiPublished in: British journal of clinical pharmacology (2020)
Genotype-guided antiplatelet treatment could decrease the risk of MACE, stent thrombosis and MI in patients with coronary artery disease or undergoing percutaneous coronary intervention, without increasing the risk of bleeding over a long follow-up period. The decreased risk of efficacy outcomes was more obvious in cohort studies. Well-organized RCTs and clinical trials are required to verify the benefit of genotype-guided therapy.
Keyphrases
- clinical trial
- percutaneous coronary intervention
- atrial fibrillation
- acute coronary syndrome
- acute myocardial infarction
- type diabetes
- randomized controlled trial
- coronary artery disease
- pulmonary embolism
- stem cells
- heart failure
- mesenchymal stem cells
- st elevation myocardial infarction
- left ventricular
- replacement therapy
- skeletal muscle
- insulin resistance